The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2026
Filed:
Sep. 01, 2020
Applicant:
Camurus Ab, Lund, SE;
Inventor:
Fredrik Tiberg, Lund, SE;
Assignee:
Camurus AB, Lund, SE;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61P 25/36 (2006.01);
U.S. Cl.
CPC ...
A61K 31/485 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61P 25/36 (2018.01);
Abstract
A lipid controlled-release formulation comprising: a) about 30 to about 50 wt % of at least one diacyl glycerol; b) about 30 to about 50 wt % of at least one phosphatidylcholine; c) about 5 to about 15 wt % ethanol; d) about 0.05 to about 0.5 wt % buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.